13.00 USD
▲-0.01+0.08%
盘后 12.91 -0.62%
2026-08-03
市值
$520.00M
市盈率
—
EPS
-1.11
股息率
—
52 周区间
0.88 – 17.25
成交量
179.34K
Beta
1.11
目标价
28.60
52W 低 0.8852W 高 17.25
价格走势
公司简介
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RA...